AstraZeneca: EU approves AstraZeneca's Imfinziin combo with chemotherapy to treat patients with resectable nonsmall cell lung cancer

AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union (EU) for the treatment of adults with resectable non─small cell lung cancer (NSCLC) at high risk of